Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2013
Reporting Period: Quarter ended March 31, 2013
This filing serves as a notification that the company announced its financial results for the first quarter of 2013. The detailed financial data is contained within the press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended March 31, 2013.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The filing explicitly states that the information in the press release is furnished and not filed, limiting the disclosure of detailed operational outlook within this specific document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 6, 2013) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical development milestones and pipeline updates mentioned in the press release.
- Confirm any updated financial guidance or cash runway projections provided in the full press release.
- Check for any material agreements or partnership announcements detailed in the attached exhibit.